A Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center found that BK virus (BKV)-specific T cells from healthy donors were safe and effective as an off-the-shelf therapy for BKV-associated hemorrhagic cystitis (BKV-HC), a painful complication common after allogeneic stem cell transplants for patients with leukemia or lymphoma. The study was published today in the Journal of Clinical Oncology.
The North Texas A Conversation With a Living Legend® raised $1 million this week in a virtual version of the signature fundraising event benefiting The University of Texas
MD Anderson Cancer Center. The 31st annual event honored Admiral William H. McRaven, U.S. Navy, Retired, in an interview Nov. 16 with CBS News’ Bob Schieffer. Proceeds will benefit MD Anderson’s Moon Shots Program®, a collaborative effort to accelerate the development of scientific discoveries into clinical advances that save patients’ lives.
Phase I trial finds neoadjuvant combination checkpoint inhibitors (anti-CTLA-4 plus anti-PD-1) was well tolerated and showed early signs of activity in certain patients with bladder cancer. These patients cannot be treated with chemotherapy and have no standard treatment options available.
A combination of two biomarkers was predictive of improved clinical responses and prolonged survival following treatment with immune checkpoint inhibitors in patients with advanced bladder cancers.
MD Anderson and Ipsen have advanced a new targeted therapy into clinical trials for certain patients with lung and ovarian cancers. Details are being presented at the AACR Annual Meeting.
A subset of patients with metastatic prostate cancer and specific markers of immune activity responded well to treatment with immune checkpoint inhibitors, according to results of a Phase II trial.
Researchers at The University of Texas MD Anderson Cancer Center have identified a tenacious subset of immune macrophages that thwart treatment of glioblastoma with anti-PD-1 checkpoint blockade, elevating a new potential target for treating the almost uniformly lethal brain tumor.
Boehringer Ingelheim and MD Anderson have announced a new multi-year partnership to conduct collaborative research, combining the drug-development capabilities of MD Anderson with the pipeline of novel medicines from Boehringer Ingelheim.